Can a pill combo keep melanoma from coming back?

NCT ID NCT04666272

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how well and how safely a combination of two cancer drugs, dabrafenib and trametinib, works when given after surgery to Chinese patients with stage III melanoma that has a specific gene change (BRAF V600). The goal is to see if the drugs help delay the cancer's return. About 78 patients will be followed over time, and researchers will track how long they stay cancer-free and any side effects they experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dabrafenib and trametinib (cancer drugs taken as pills)
What this could lead to: If successful, this could confirm that combining these drugs after surgery helps delay melanoma recurrence in Chinese patients.
What could go wrong: This is an observational study with no control group, so results may be less reliable. Side effects from the drugs can be serious, and the small size (78 patients) limits how broadly findings apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Novartis Investigative Site

Fuzhou, Fujian, 350014, China
Novartis Investigative Site

Zhengzhou, Henan, 410100, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Changsha, Hunan, 410013, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Kunming, Yunnan, 650106, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310022, China
Novartis Investigative Site

Beijing, 100036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.